Semaglutide Vs Tirzepatide
Provider evaluation · Appropriate testing · Ongoing monitoring
One Drug Won The Trial. That Does Not Decide Your Prescription.
Semaglutide is the active ingredient in Ozempic and Wegovy and acts on the GLP-1 receptor. Tirzepatide is the active ingredient in Mounjaro and Zepbound and acts on both GLP-1 and GIP. That mechanical difference is the starting point for everything else. SURMOUNT-5, the first head-to-head trial, randomized 751 adults with obesity and without diabetes to one or the other for 72 weeks. Tirzepatide produced greater weight reduction and greater improvement in blood pressure, HbA1c, fasting insulin, triglycerides, and HDL. Body composition data across the trial programs also suggests tirzepatide loses a smaller share of lean mass. Here is what a trial average does not tell you. It does not tell you which one you will tolerate. It does not account for the other medications you take, your insurance coverage, what is actually available, or whether you can stay on a titration schedule long enough for any of it to matter. The medication that works is the one you stay on. At T Clinics USA that decision is made in person, with your labs, at our Naples, Fort Myers, or Coral Springs clinic. Results vary by individual.
A Comparison, Not A Recommendation
Both medications are prescribed at T Clinics USA after an in-person evaluation. Which one is a clinical decision made with your labs.
How It Works






